Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis

Company Overview

Salarius Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults. Seclidemstat is currently being evaluated in Phase 2 clinical studies, where the company is investigating its efficacy and safety profile in patients with relapsed or refractory disease.

In addition to its lead program, Salarius maintains a robust preclinical pipeline of small‐molecule candidates targeting fusion‐driven cancers and other oncology indications. These programs leverage proprietary chemistry platforms to identify novel inhibitors of NEDD8‐activating enzymes and other epigenetic regulators. By addressing oncogenic fusion proteins and key regulatory enzymes that drive tumor growth, Salarius aims to expand its portfolio of precision therapies for patients with unmet medical needs.

Founded in 2014 and headquartered in Houston, Texas, Salarius Pharmaceuticals has assembled a management team with extensive experience in oncology drug development, regulatory strategy, and commercialization. The company’s clinical trials are conducted primarily in the United States, with plans to extend development activities into Europe and other regions as part of its global strategy. Salarius also collaborates with academic institutions, patient advocacy groups and research consortia to advance its programs and accelerate the delivery of new cancer therapies to the clinic.

Key Stats

• Today's Range: $0.69 to $0.90
• 50-Day Range: $0.54 to $0.87
• 52-Week Range: $0.51 to $34.65
• Volume: 5.99 million shs
• Average Volume: 808,890 shs
• Market Capitalization: $4.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

SLRX Stock Analysis - Frequently Asked Questions

How were Salarius Pharmaceuticals' earnings last quarter?

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($33.00) by $32.55.

When did Salarius Pharmaceuticals' stock split?

Salarius Pharmaceuticals shares reverse split before market open on Tuesday, August 19th 2025.The 1-15 reverse split was announced on Tuesday, August 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 19th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Salarius Pharmaceuticals IPO?

Salarius Pharmaceuticals (SLRX) raised $70 million in an initial public offering on Thursday, January 29th 2015. The company issued 5,400,000 shares at $12.00-$14.00 per share.

What other stocks do shareholders of Salarius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Salarius Pharmaceuticals investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), Meta Platforms (META), T2 Biosystems (TTOO), NIO (NIO) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLRX
• Previous Symbol: NASDAQ:FLKS
• CIK: 1615219
• Web: www.salariuspharma.com
• Phone: (832) 834-6992
• Fax: N/A
• Employees: 20
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($33.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -401.05%
• Return on Assets: -155.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.28
• Quick Ratio: 3.28

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.31 per share
• Price / Book: 0.06

Miscellaneous

• Outstanding Shares: 5,862,000
• Free Float: 5,844,000
• Market Cap: $4.89 million
• Optionable: Not Optionable
• Beta: 0.33